Cargando…

How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma

SIMPLE SUMMARY: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were drugs originally intended for the management of diabetes, while their role on the treatment of nonalcoholic steatohepatitis (NASH), and NASH-related hepatocellular carcinoma (HCC), has been at the forefront of medical investi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arvanitakis, Konstantinos, Koufakis, Theocharis, Kotsa, Kalliopi, Germanidis, Georgios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562923/ https://www.ncbi.nlm.nih.gov/pubmed/36230573 http://dx.doi.org/10.3390/cancers14194651

Ejemplares similares

Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care
por: Rentzeperi, Elpiniki, et al.
Publicado: (2022)

Managing Diabetes in the Era of Financial Crisis: Need to Look Beyond the Obvious
por: Koufakis, Theocharis, et al.
Publicado: (2018)

Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
por: Vasdeki, Dimitra, et al.
Publicado: (2022)

Changes in the Global Epidemiology of Type 1 Diabetes in an Evolving Landscape of Environmental Factors: Causes, Challenges, and Opportunities
por: Ogrotis, Ioannis, et al.
Publicado: (2023)

Epidemiological, Pathophysiological, and Clinical Considerations on the Interplay between Thyroid Disorders and Type 2 Diabetes Mellitus
por: Grigoriadis, Gregory, et al.
Publicado: (2023)

Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy
por: Arvanitakis, Konstantinos, et al.
Publicado: (2021)

Potential Role of Ultrafast-acting Insulin Analogues in the Treatment of Diabetic Ketoacidosis
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Changes in dietary intake of aspartic acid during and after intermittent fasting correlate with an improvement in fasting glucose in overweight individuals
por: Karras, Spyridon N., et al.
Publicado: (2023)

COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong
por: Koufakis, Theocharis, et al.
Publicado: (2022)

The importance of sleep quality, quantity, and chronotype in the management of diabetes: Is it time to wake up?
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Antiatherosclerotic Effects of Sodium-Glucose Cotransporter 2 Inhibitors: An Underrecognized Piece of the Big Puzzle?
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Interplay of Extracellular Vesicles and TLR4 Signaling in Hepatocellular Carcinoma Pathophysiology and Therapeutics
por: Papadakos, Stavros P., et al.
Publicado: (2023)

The Role of TLR4 in the Immunotherapy of Hepatocellular Carcinoma: Can We Teach an Old Dog New Tricks?
por: Papadakos, Stavros P., et al.
Publicado: (2023)

Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy
por: Arvanitakis, Konstantinos, et al.
Publicado: (2022)

Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches
por: Arvanitakis, Konstantinos, et al.
Publicado: (2023)

Deconvoluting the Biological Roles of Vitamin D-Binding Protein During Pregnancy: A Both Clinical and Theoretical Challenge
por: Karras, Spyridon N., et al.
Publicado: (2018)

Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun
por: Karras, Spyridon N, et al.
Publicado: (2019)

Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases
por: Koufakis, Theocharis, et al.
Publicado: (2021)

Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation
por: Papadakos, Stavros P., et al.
Publicado: (2023)

Looking deeper into the findings of DARE-19: Failure or an open door to future success?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

The role of sexual dimorphism in susceptibility to SARS-CoV-2 infection, disease severity, and mortality: facts, controversies and future perspectives
por: Pegiou, Stavroula, et al.
Publicado: (2021)

Azospirillum: benefits that go far beyond biological nitrogen fixation
por: Fukami, Josiane, et al.
Publicado: (2018)

Fasting insulin levels correlate with the frequency of hypoglycemic events in people with type 2 diabetes on treatment with sulfonylureas: A pilot study
por: Kolokas, Konstantinos, et al.
Publicado: (2020)

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

Effects of Christian Orthodox Fasting Versus Time-Restricted Eating on Plasma Irisin Concentrations Among Overweight Metabolically Healthy Individuals
por: Karras, Spyridon N., et al.
Publicado: (2021)

The Relationship between Primary Hyperparathyroidism and Thrombotic Events: Report of Three Cases and a Review of Potential Mechanisms
por: Koufakis, Theocharis, et al.
Publicado: (2018)

TAV-in-TAV and Beyond: How Far Can We Go?
por: Taramasso, Maurizio, et al.
Publicado: (2023)

From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Adverse pregnancy outcomes in women with celiac disease: a systematic review and meta-analysis
por: Arvanitakis, Konstantinos, et al.
Publicado: (2023)

The Liver Cancer Immune Microenvironment: Emerging Concepts for Myeloid Cell Profiling with Diagnostic and Therapeutic Implications
por: Arvanitakis, Konstantinos, et al.
Publicado: (2023)

Biocatalytic membrane: Go far beyond enzyme immobilization
por: Luo, Jianquan, et al.
Publicado: (2020)

Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
por: Veneti, Stavroula, et al.
Publicado: (2020)

First Report of Diabetes Phenotype due to a Loss-of-Function ABCC8 Mutation Previously Known to Cause Congenital Hyperinsulinism
por: Koufakis, Theocharis, et al.
Publicado: (2019)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Vitamin D Alleviates Anxiety and Depression in Elderly People with Prediabetes: A Randomized Controlled Study
por: Zaromytidou, Evangelia, et al.
Publicado: (2022)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes
por: Mahapatra, Manoj Kumar, et al.
Publicado: (2022)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
por: Sofogianni, Areti, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3qansq79kggmvk9tvcdc39o7j6